Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The MagnaSafe-2 Registry: Assessing the Risks of Magnetic Resonance Imaging in Three Patient Groups: (1) an MRI at a Magnet Field Strength of 3-tesla, (2) a "Mixed-vendor" or a Same Vendor "Mixed-component" Platform at 1.5-tesla or 3-tesla, or (3) a System With an Abandoned, Epicardial, or Fractured Lead at 1.5-tesla.

NCT07189728 is registered in ClinicalTrials.gov with The Scripps Research Institute as lead sponsor.

NCT NCT07189728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The MagnaSafe-2 Registry: Assessing the Risks of Magnetic Resonance Imaging in Three Patient Groups: (1) an MRI at a Magnet Field Strength of 3-tesla, (2) a "Mixed-vendor" or a Same Vendor "Mixed-component" Platform at 1.5-tesla or 3-tesla, or (3) a System With an Abandoned, Epicardial, or Fractured Lead at 1.5-tesla.
Lead sponsor
The Scripps Research Institute
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
January 1, 2031
Enrollment
1,500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

implantable cardioverter defibrillator (icd), mri imaging, pacemakers